Home » Topics » BioWorld Science

BioWorld Science
RSS

CRM-1.13.1: Nicotinic agonist based on lobeline

Aug. 30, 1996

Memantine enters phase I for AIDS-related dementia, painful peripheral neuropathies

Aug. 30, 1996

Synapton phase III trials concluded

Aug. 30, 1996

Prednisone suppresses acute phase in AD patients

Aug. 30, 1996

Botulinum toxin effective in treating writer's cramp

Aug. 30, 1996

Botulinum toxin effective in reducing upper limb spasticity

Aug. 30, 1996

Roche files for approval of Tasmar

Aug. 30, 1996

Tegretol-XR launched in U.S.

Aug. 30, 1996

Cypress Bioscience/PRP merger imminent

Aug. 30, 1996

Celox Laboratories' ViaStem covered under patent

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.